Accessibility Menu
 
Kymera Therapeutics logo

Kymera Therapeutics

(NASDAQ) KYMR

Current Price$78.33
Market Cap$6.38B
Since IPO (2020)+135%
5 Year+105%
1 Year+159%
1 Month-14%

Kymera Therapeutics Financials at a Glance

Market Cap

$6.38B

Revenue (TTM)

$39.20M

Net Income (TTM)

$311.40M

EPS (TTM)

$-3.68

P/E Ratio

-21.24

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Price

$78.33

Volume

671,535

Open

$80.18

Previous Close

$78.16

Daily Range

$78.05 - $81.26

52-Week Range

$19.45 - $103.00

KYMR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kymera Therapeutics

Industry

Biotechnology

Employees

238

CEO

Nello Mainolfi, PhD

Headquarters

Watertown, MA 02472, US

KYMR Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-9%

Net Income Margin

-8%

Return on Equity

-26%

Return on Capital

-21%

Return on Assets

-18%

Earnings Yield

-4.71%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.38B

Shares Outstanding

81.64M

Volume

671.53K

Short Interest

0.00%

Avg. Volume

767.39K

Financials (TTM)

Gross Profit

$39.20M

Operating Income

$349.40M

EBITDA

$303.06M

Operating Cash Flow

$232.89M

Capital Expenditure

$1.45M

Free Cash Flow

$234.34M

Cash & ST Invst.

$848.28M

Total Debt

$82.25M

Kymera Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$2.86M

-61.3%

Gross Profit

$79.04M

+968.9%

Gross Margin

27.64%

N/A

Market Cap

$6.38B

N/A

Market Cap/Employee

$30.68M

N/A

Employees

208

N/A

Net Income

$87.03M

-23.0%

EBITDA

$85.15M

-23.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$766.02M

+91.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$68.50M

-8.2%

Short Term Debt

$13.76M

+4.9%

Return on Assets

-17.87%

N/A

Return on Invested Capital

-21.05%

N/A

Free Cash Flow

$66.85M

-6.6%

Operating Cash Flow

$66.75M

-8.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PRAXPraxis Precision Medicines, Inc.
$290.10-4.16%
ACLXArcellx, Inc.
$114.57-0.04%
IMVTImmunovant, Inc.
$23.98-5.44%
AKROAkero Therapeutics, Inc.
$54.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About KYMR

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.